The Role of Inflammatory and Oxidative Stress Mechanisms in the Pathogenesis of Parkinson’s Disease: Focus on Astrocytes

Neuroinflammation plays a key role in the pathogenesis of Parkinson’s disease (PD). Epidemiologic, animal, human, and therapeutic studies support the role of oxidative stress and inflammatory cascade in initiation and progression of PD. In Parkinson’s disease pathophysiology, activated glia affects neuronal injury and death through production of neurotoxic factors like glutamate, S100B, tumor necrosis factor alpha (TNF-α), prostaglandins, and reactive oxygen and nitrogen species. As disease progresses, inflammatory secretions engage neighboring cells, including astrocytes and endothelial cells, resulting in a vicious cycle of autocrine and paracrine amplification of inflammation leading to neurodegeneration. The exact mechanism of these inflammatory mediators in the disease progression is still poorly understood. In this review, we highlight and discuss the mechanisms of oxidative stress and inflammatory mediators by which they contribute to the disease progression. Particularly, we focus on the altered role of astroglial cells that presumably initiate and execute dopaminergic neurodegeneration in PD. In conclusion, we focus on the molecular mechanism of neurodegeneration, which contributes to the basic understanding of the role of neuroinflammation in PD pathophysiology.

[1]  J. S. Schneider,et al.  Astrocytic Responses to the Dopaminergic Neurotoxin 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Cat and Mouse Brain , 1988, Journal of neuropathology and experimental neurology.

[2]  V Balasingam,et al.  Reactive astrogliosis in the neonatal mouse brain and its modulation by cytokines , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[3]  M. Ross,et al.  Cyclo-Oxygenase-2 Gene Expression in Neurons Contributes to Ischemic Brain Damage , 1997, The Journal of Neuroscience.

[4]  Luigi Aloe,et al.  TNF-α expressed in the brain of transgenic mice lowers central tyroxine hydroxylase immunoreactivity and alters grooming behavior , 1997, Neuroscience Letters.

[5]  P. Damier,et al.  Glial cells and inflammation in parkinson's disease: A role in neurodegeneration? , 1998, Annals of neurology.

[6]  K. Davis,et al.  Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. , 1998, Archives of general psychiatry.

[7]  R. Djaldetti,et al.  IL-1 beta, IL-2, IL-6 and TNF-alpha production by peripheral blood mononuclear cells from patients with Parkinson's disease. , 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  K. Prasad,et al.  Multiple antioxidants in the prevention and treatment of Parkinson's disease. , 1999, Journal of the American College of Nutrition.

[9]  R. Djaldetti,et al.  IL-1β, IL-2, IL-6 and TNF-α production by peripheral blood mononuclear cells from patients with Parkinson's disease , 1999 .

[10]  M. Sogorb,et al.  Dichlorophenyl phosphoramidates as substrates for avian and mammalian liver phosphotriesterases: activity levels, calcium dependence and stereospecificity. , 1999, Chemico-biological interactions.

[11]  T. Peng,et al.  Mitochondrial dysfunction in Parkinson's disease. , 1999, Biochemical Society symposium.

[12]  S. Mandel,et al.  MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies , 2000, Journal of Neurology.

[13]  P. Mcgeer,et al.  R-(−)-Deprenyl Inhibits Monocytic THP-1 Cell Neurotoxicity Independently of Monoamine Oxidase Inhibition , 2000, Experimental Neurology.

[14]  H. Ichinose,et al.  Changes in cytokines and neurotrophins in Parkinson's disease. , 2000, Journal of neural transmission. Supplementum.

[15]  A. Minagar,et al.  The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis , 2002, Journal of the Neurological Sciences.

[16]  J. Cano,et al.  The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. , 2002, Journal of neurochemistry.

[17]  M. Horne,et al.  The Role of Interleukin-1, Interleukin-6, and Glia in Inducing Growth of Neuronal Terminal Arbors in Mice , 2002, The Journal of Neuroscience.

[18]  S. Speciale,et al.  MPTP: insights into parkinsonian neurodegeneration. , 2002, Neurotoxicology and teratology.

[19]  J. Cano,et al.  The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh‐TNF‐α, IL‐1β and IFN‐γ , 2002 .

[20]  Andis Klegeris,et al.  Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity , 2002, Neurobiology of Aging.

[21]  E. Hirsch,et al.  The Role of Glial Reaction and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.

[22]  Dong-Kug Choi,et al.  Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Allan,et al.  The interleukin-1 system: an attractive and viable therapeutic target in neurodegenerative disease. , 2003, Current drug targets. CNS and neurological disorders.

[24]  M. Beal Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.

[25]  P. Carvey,et al.  Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease. , 2003, Frontiers in bioscience : a journal and virtual library.

[26]  W. Willett,et al.  Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. , 2003, Archives of neurology.

[27]  M. Barrachina,et al.  Dopamine induces autophagic cell death and α‐synuclein increase in human neuroblastoma SH‐SY5Y cells , 2003, Journal of neuroscience research.

[28]  L. Minghetti Cyclooxygenase‐2 (COX‐2) in Inflammatory and Degenerative Brain Diseases , 2004, Journal of neuropathology and experimental neurology.

[29]  Ling-chun Chen,et al.  Temporal gene expression patterns in G93A/SOD1 mouse , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[30]  E. Ongini,et al.  Attenuation of chronic neuroinflammation by a nitric oxide‐releasing derivative of the antioxidant ferulic acid , 2004, Journal of neurochemistry.

[31]  E. Feldman,et al.  Neuroinflammation, COX-2, and ALS—a dual role? , 2004, Experimental Neurology.

[32]  C. Asselin,et al.  IL-1-dependent regulation of C/EBPd transcriptional activity , 2005 .

[33]  F. Breedveld [Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept]. , 2005, Nederlands tijdschrift voor geneeskunde.

[34]  C. Asselin,et al.  IL-1 beta-dependent regulation of C/EBP delta transcriptional activity. , 2005, Biochemical and biophysical research communications.

[35]  S. Tzeng,et al.  Prostaglandins and cyclooxygenases in glial cells during brain inflammation. , 2005, Current drug targets. Inflammation and allergy.

[36]  T. Montine,et al.  Deletion of the Prostaglandin E2 EP2 Receptor Reduces Oxidative Damage and Amyloid Burden in a Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[37]  K. Hensley,et al.  On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. , 2006, Antioxidants & redox signaling.

[38]  A. Favier Stress oxydant et pathologies humaines , 2006 .

[39]  B. Jiang,et al.  Catalpol protects dopaminergic neurons from LPS-induced neurotoxicity in mesencephalic neuron-glia cultures. , 2006, Life sciences.

[40]  E. Katunina,et al.  [Antioxidants in complex treatment of Parkinson's disease]. , 2006, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[41]  W. Kukull,et al.  Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[42]  W. Tsai,et al.  Divergent role of calcium on Abeta- and MPTP-induced cell death in SK-N-SH neuroblastoma. , 2006, Life sciences.

[43]  K. Weiss,et al.  Hypertrophic pachymeningitis in rheumatoid arthritis after adalimumab administration. , 2006, The Journal of rheumatology.

[44]  A. Favier [Oxidative stress in human diseases]. , 2006, Annales pharmaceutiques francaises.

[45]  J. Relton,et al.  Neuroinflammation in Parkinson’s patients and MPTP-treated mice is not restricted to the nigrostriatal system: Microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb , 2007, Experimental Gerontology.

[46]  V. Cuomo,et al.  Cannabidiol in vivo blunts β‐amyloid induced neuroinflammation by suppressing IL‐1β and iNOS expression , 2007 .

[47]  G. Bing,et al.  Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system , 2007, Journal of neurochemistry.

[48]  G. Deuschl,et al.  Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. , 2007, Current pharmaceutical design.

[49]  S. Tufik,et al.  The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. , 2007, European journal of pharmacology.

[50]  J. Rogers,et al.  Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? , 2007, International review of neurobiology.

[51]  T. Bisogno,et al.  Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro , 2007, Journal of Molecular Medicine.

[52]  E. Ling,et al.  Microglial activation and its implications in the brain diseases. , 2007, Current medicinal chemistry.

[53]  W. Marks,et al.  Epidemiology of Parkinson's disease. , 2007, Disease-a-month : DM.

[54]  V. Cuomo,et al.  Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. , 2007, British journal of pharmacology.

[55]  Takashi Mori,et al.  Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 2007, Brain Research.

[56]  Hong Yuan 袁红,et al.  Pathogenesis of Parkinson’s disease: oxidative stress, environmental impact factors and inflammatory processes , 2007, Neuroscience Bulletin.

[57]  B. Li,et al.  The NADPH oxidase is involved in lipopolysaccharide-mediated motor neuron injury , 2008, Brain Research.

[58]  D. Doudet,et al.  Neuromodulation in a minipig MPTP model of Parkinson disease , 2008, British journal of neurosurgery.

[59]  M. Mena,et al.  Glial Cells as Players in Parkinsonism: The “Good,” the “Bad,” and the “Mysterious” Glia , 2008, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[60]  G. Miller,et al.  PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity , 2008, Neuropeptides.

[61]  A. Stępień,et al.  Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism , 2008, Neuroscience Letters.

[62]  S. Przedborski,et al.  Oxidative Stress in Parkinson's Disease , 2008, Annals of the New York Academy of Sciences.

[63]  M. Mena,et al.  Glial Dysfunction in Parkin Null Mice: Effects of Aging , 2008, The Journal of Neuroscience.

[64]  M. Asanuma,et al.  Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease. , 2008, Current pharmaceutical design.

[65]  D. Surmeier,et al.  Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. , 2008, Parkinsonism & related disorders.

[66]  J. Gustafsson,et al.  Liver X receptor β (LXRβ): A link between β-sitosterol and amyotrophic lateral sclerosis–Parkinson's dementia , 2008, Proceedings of the National Academy of Sciences.

[67]  P. Riederer,et al.  Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability , 2008, Neurobiology of Disease.

[68]  J. Mallet,et al.  Neurotoxic Activation of Microglia Is Promoted by a Nox1-Dependent NADPH Oxidase , 2008, The Journal of Neuroscience.

[69]  P. Mcgeer,et al.  Glial reactions in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[70]  B. Carleton,et al.  Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: A retrospective cohort study , 2008, Journal of Clinical Neuroscience.

[71]  I Persson,et al.  What is the harm-benefit ratio of Cox-2 inhibitors? , 2008, International journal of epidemiology.

[72]  P. Brundin,et al.  Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease , 2008, Neurobiology of Disease.

[73]  D. D. Di Monte,et al.  Macrophage Antigen Complex-1 Mediates Reactive Microgliosis and Progressive Dopaminergic Neurodegeneration in the MPTP Model of Parkinson’s Disease1 , 2008, The Journal of Immunology.

[74]  R. Kuljiš,et al.  The Role of Neuroimmunomodulation in Alzheimer's Disease , 2009, Annals of the New York Academy of Sciences.

[75]  S. Sugama,et al.  Microglial activation is inhibited by corticosterone in dopaminergic neurodegeneration , 2009, Journal of Neuroimmunology.

[76]  E. Buerger,et al.  Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole , 2009, Current medical research and opinion.

[77]  M. Tansey,et al.  Neuroinflammation in Parkinson’s Disease , 2009, Journal of Neuroimmune Pharmacology.

[78]  W. Wurst,et al.  Regulation of astrocyte inflammatory responses by the Parkinson's disease‐associated gene DJ–1 , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[79]  Mei Yu,et al.  Elevated interleukin-1β induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine aggravating dopaminergic neurodegeneration in old male mice , 2009, Brain Research.

[80]  M. Graeber,et al.  Microglia: biology and pathology , 2009, Acta Neuropathologica.

[81]  H. Kato,et al.  Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice. , 2009, Experimental and molecular pathology.

[82]  M. Niso-Santano,et al.  Curcumin enhances paraquat-induced apoptosis of N27 mesencephalic cells via the generation of reactive oxygen species. , 2009, Neurotoxicology.

[83]  F. Bosetti,et al.  Cyclooxygenase-1 null mice show reduced neuroinflammation in response to β-amyloid , 2009, Aging.

[84]  P. Gatev,et al.  Interactions between cortical rhythms and spiking activity of single basal ganglia neurons in the normal and parkinsonian state. , 2009, Cerebral cortex.

[85]  D. Souza,et al.  Interleukin-6 Serum Levels in Patients with Parkinson’s Disease , 2009, Neurochemical Research.

[86]  J. Cano,et al.  Zocor Forte (simvastatin) has a neuroprotective effect against LPS striatal dopaminergic terminals injury, whereas against MPP+ does not. , 2009, European journal of pharmacology.

[87]  Peter Ponsaerts,et al.  Microglia: gatekeepers of central nervous system immunology , 2009, Journal of leukocyte biology.

[88]  M. Peter,et al.  Selective types of autophagy in yeast. , 2009, Biochimica et biophysica acta.

[89]  R. Niranjan,et al.  Evaluation of guggulipid and nimesulide on production of inflammatory mediators and GFAP expression in LPS stimulated rat astrocytoma, cell line (C6). , 2010, Journal of ethnopharmacology.

[90]  C. Haass,et al.  Mitochondrial dysfunction in Parkinson's disease. , 2010, Biochimica et biophysica acta.

[91]  S. Nah,et al.  Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration , 2010, Neurochemistry International.

[92]  M. Goldberg,et al.  Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention , 2010, Neurobiology of Disease.

[93]  A. Ghio,et al.  Dopaminergic neurotoxicity following pulmonary exposure to manganese-containing welding fumes , 2010, Archives of Toxicology.

[94]  F. Ciencias Astrocyte-derived GDNF is a potent inhibitor of microglial activation , 2010 .

[95]  R. Niranjan,et al.  The mechanism of action of MPTP-induced neuroinflammation and its modulation by melatonin in rat astrocytoma cells, C6 , 2010, Free radical research.

[96]  K. Suk,et al.  Effects of Obovatol on GSH Depleted Glia-Mediated Neurotoxicity and Oxidative Damage , 2012, Journal of Neuroimmune Pharmacology.

[97]  M. Cookson,et al.  Astrocytes in Parkinson’s disease and DJ‐1 , 2011, Journal of neurochemistry.

[98]  R. Akundi,et al.  Increased Mitochondrial Calcium Sensitivity and Abnormal Expression of Innate Immunity Genes Precede Dopaminergic Defects in Pink1-Deficient Mice , 2011, PloS one.

[99]  M. Tansey,et al.  TNF: a key neuroinflammatory mediator of neurotoxicity and neurodegeneration in models of Parkinson's disease. , 2011, Advances in experimental medicine and biology.

[100]  E. Hirsch,et al.  Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism , 2011, Proceedings of the National Academy of Sciences.

[101]  K. Tieu,et al.  Astrocytes and therapeutics for Parkinson’s disease , 2010, Neurotherapeutics.

[102]  L. Della Corte,et al.  Anti-inflammatory actions of a taurine analogue, ethane β-sultam, in phagocytic cells, in vivo and in vitro. , 2011, Biochemical pharmacology.

[103]  R. Niranjan,et al.  Guggulipid and Nimesulide Differentially Regulated Inflammatory Genes mRNA Expressions via Inhibition of NF-kB and CHOP Activation in LPS-Stimulated Rat Astrocytoma Cells, C6 , 2011, Cellular and Molecular Neurobiology.

[104]  F. Cicchetti,et al.  The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration , 2011, Journal of Neuroinflammation.

[105]  J. Andersen,et al.  Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: Implications for early intervention on disease progression , 2011, Neurobiology of Disease.

[106]  Sunhee C. Lee,et al.  Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflammatory miR‐155 and miR‐155* , 2011, Glia.

[107]  R. Niranjan,et al.  Melatonin attenuated mediators of neuroinflammation and alpha-7 nicotinic acetylcholine receptor mRNA expression in lipopolysaccharide (LPS) stimulated rat astrocytoma cells, C6 , 2012, Free radical research.

[108]  Xavier Golay,et al.  Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[109]  W. Poewe,et al.  Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy , 2012, Acta Neuropathologica.

[110]  I. Krizbai,et al.  Activation of Cannabinoid Receptor 2 Attenuates Leukocyte–Endothelial Cell Interactions and Blood–Brain Barrier Dysfunction under Inflammatory Conditions , 2012, The Journal of Neuroscience.

[111]  J. Chavis,et al.  Resveratrol effects on astrocyte function: relevance to neurodegenerative diseases. , 2012, Biochemical and biophysical research communications.

[112]  S. Sugama,et al.  Neuroinflammation in Parkinson's Disease and Related Disorders: A Lesson from Genetically Manipulated Mouse Models of α-Synucleinopathies , 2012, Parkinson's disease.

[113]  M. Burkovetskaya,et al.  Neuroinflammation alters voltage-dependent conductance in striatal astrocytes. , 2012, Journal of neurophysiology.

[114]  R. Niranjan,et al.  The effect of guggulipid and nimesulide on MPTP-induced mediators of neuroinflammation in rat astrocytoma cells, C6. , 2012, Chemico-biological interactions.

[115]  D. Walker,et al.  Cobalt(II) β-ketoaminato complexes as novel inhibitors of neuroinflammation. , 2012, European journal of pharmacology.

[116]  B. Barres,et al.  Genomic Analysis of Reactive Astrogliosis , 2012, The Journal of Neuroscience.

[117]  Mancheva-Ganeva Velina,et al.  Licensed under Creative Commons Attribution Cc by Oxidative Stress in Parkinson's Disease , 2022 .